MAGE-c2-specific TCRs combined with epigenetic drug-enhanced antigenicity yield robust and tumor-selective T cell responses

Journal of Immunology

Volumn 197, Issue 6, 2016, Pages 2541-2552

  Kunert, Andre ^a   Van Brakel, Mandy ^a   Van Steenbergen Langeveld, Sabine ^a   Da Silva, Marvin ^a   Coulie, Pierre G ^b   Lamers, Cor ^a   Sleijfer, Stefan ^a   Debets, Reno ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b DE DUVE INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; B7 ANTIGEN; CD86 ANTIGEN; EPITOPE; MELANOMA ANTIGEN; MELANOMA ASSOCIATED NATIGEN C2; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VALPROIC ACID; CD274 PROTEIN, HUMAN; CD86 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MAGEC2 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; BLADDER CANCER; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; EPIGENETIC DRUG ENHANCED ANTIGENICITY; EPIGENETICS; GENE; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOREGULATION; MC2 GENE; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; UPREGULATION; VACCINATION; ADOPTIVE IMMUNOTHERAPY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD274; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, NEOPLASM; AZACITIDINE; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; VALPROIC ACID;

EID: 84988970056     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502024     Document Type: Article

References (61)

1. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
2. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
3. Parkhurst, M. R., J. C. Yang, R. C. Langan, M. E. Dudley, D. A. Nathan, S. A. Feldman, J. L. Davis, R. A. Morgan, M. J. Merino, R. M. Sherry, et al. 2011. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19: 620-626.
4. Robbins, P. F., R. A. Morgan, S. A. Feldman, J. C. Yang, R. M. Sherry, M. E. Dudley, J. R. Wunderlich, A. V. Nahvi, L. J. Helman, C. L. Mackall, et al. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29: 917-924.
5. Rapoport, A. P., E. A. Stadtmauer, G. K. Binder-Scholl, O. Goloubeva, D. T. Vogl S. F. Lacey, A. Z. Badros, A. Garfall, B. Weiss, J. Finklestein, et al. 2015. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigenspecific antitumor effects in myeloma. Nat. Med. 21: 914-921.
6. Robbins, P. F., S. H. Kassim, T. L. Tran, J. S. Crystal, R. A. Morgan, S. A. Feldman, J. C. Yang, M. E. Dudley, J. R. Wunderlich, R. M. Sherry, et al. 2015. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21: 1019-1027.
7. Morgan, R. A., N. Chinnasamy, D. Abate-Daga, A. Gros, P. F. Robbins, Z. Zheng, M. E. Dudley, S. A. Feldman, J. C. Yang, R. M. Sherry, et al. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36: 133-151.
8. van den Berg, J. H., R. Gomez-Eerland, B. van de Wiel, L. Hulshoff, D. van den Broek, A. Bins, H. L. Tan, J. V. Harper, N. J. Hassan, B. K. Jakobsen, et al. 2015. Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor. Mol. Ther. 23: 1541-1550.
9. Linette, G. P., E. A. Stadtmauer, M. V. Maus, A. P. Rapoport, B. L. Levine, L. Emery, L. Litzky, A. Bagg, B. M. Carreno, P. J. Cimino, et al. 2013. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122: 863-871.
10. Lucas, S., E. De Plaen, and T. Boon. 2000. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int. J. Cancer 87: 55-60.
11. Hofmann, O., O. L. Caballero, B. J. Stevenson, Y. T. Chen, T. Cohen, R. Chua, C. A. Maher, S. Panji, U. Schaefer, A. Kruger, et al. 2008. Genome-wide analysis of cancer/testis gene expression. Proc. Natl. Acad. Sci. USA 105: 20422-20427.
12. Curioni-Fontecedro, A., N. Nuber, D. Mihic-Probst, B. Seifert, D. Soldini, R. Dummer, A. Knuth, M. van den Broek, and H. Moch. 2011. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS One 6: e21418.
13. Cuffel, C., J. P. Rivals, Y. Zaugg, S. Salvi, W. Seelentag, D. E. Speiser, D. Liénard, P. Monnier, P. Romero, L. Bron, and D. Rimoldi. 2011. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int. J. Cancer 128: 2625-2634.
14. Figueiredo, D. L., R. C. Mamede, G. C. Spagnoli, W. A. Silva, Jr., M. Zago, L. Neder, A. A. Jungbluth, and F. P. Saggioro. 2011. High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck 33: 702-707.
15. Yang, F., X. Zhou, X. Miao, T. Zhang, X. Hang, R. Tie, N. Liu, F. Tian, F. Wang, and J. Yuan. 2014. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast Cancer Res. Treat. 145: 23-32.
16. Yang, B., S. M. O'Herrin, J. Wu, S. Reagan-Shaw, Y. Ma, K. M. Bhat, C. Gravekamp, V. Setaluri, N. Peters, F. M. Hoffmann, et al. 2007. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 67: 9954-9962.
17. Lurquin, C., B. Lethé, E. De Plaen, V. Corbiere, I. Théate, N. van Baren, P. G. Coulie, and T. Boon. 2005. Contrasting frequencies of antitumor and antivaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201: 249-257.
18. Ma, W., C. Germeau, N. Vigneron, A. S. Maernoudt, S. Morel, T. Boon, P. G. Coulie, and B. J. Van den Eynde. 2004. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int. J. Cancer 109: 698-702.
19. Godelaine, D., J. Carrasco, F. Brasseur, B. Neyns, K. Thielemans, T. Boon, and A. Van Pel. 2007. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunol. Immunother. 56: 753-759.
20. Ma, W., N. Vigneron, J. Chapiro, V. Stroobant, C. Germeau, T. Boon, P. G. Coulie, and B. J. Van den Eynde. 2011. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy. Int. J. Cancer 129: 2427-2434.
21. Germeau, C., W. Ma, F. Schiavetti, C. Lurquin, E. Henry, N. Vigneron, F. Brasseur, B. Lethé, E. De Plaen, T. Velu, et al. 2005. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201: 241-248.
22. Carrasco, J., A. Van Pel, B. Neyns, B. Lethé, F. Brasseur, N. Renkvist, P. van der Bruggen, N. van Baren, R. Paulus, K. Thielemans, et al. 2008. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol. 180: 3585-3593.
23. Guillaume, B., V. Stroobant, M. P. Bousquet-Dubouch, D. Colau, J. Chapiro, N. Parmentier, A. Dalet, and B. J. Van den Eynde. 2012. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J. Immunol. 189: 3538-3547.
24. Chapiro, J., S. Claverol, F. Piette, W. Ma, V. Stroobant, B. Guillaume, J. E. Gairin, S. Morel, O. Burlet-Schiltz, B. Monsarrat, et al. 2006. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 176: 1053-1061.
25. van de Griend, R. J., and R. L. Bolhuis. 1984. Rapid expansion of allospecific cytotoxic T cell clones using nonspecific feeder cell lines without further addition of exogenous IL2. Transplantation 38: 401-406.
26. Obenaus, M., C. Leitao, M. Leisegang, X. Chen, I. Gavvovidis, P. van der Bruggen, W. Uckert, D. J. Schendel, and T. Blankenstein. 2015. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigennegative humanized mice. Nat. Biotechnol. 33: 402-407.
27. Straetemans, T., M. van Brakel, S. van Steenbergen, M. Broertjes, J. Drexhage, J. Hegmans, B. N. Lambrecht, C. Lamers, P. van Der Bruggen, P. G. Coulie, and R. Debets. 2012. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLADP4 epitopes as melanoma-specific immune targets. Clin. Dev. Immunol. 2012: 586314.
28. Lamers, C. H., R. A. Willemsen, P. van Elzakker, B. A. van Krimpen, J. W. Gratama, and R. Debets. 2006. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer. Cancer Gene Ther. 13: 503-509.
29. Cole, D. K., E. S. Edwards, K. K. Wynn, M. Clement, J. J. Miles, K. Ladell, J. Ekeruche, E. Gostick, K. J. Adams, A. Skowera, et al. 2010. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J. Immunol. 185: 2600-2610.
30. Goodyear, O., A. Agathanggelou, I. Novitzky-Basso, S. Siddique, T. McSkeane, G. Ryan, P. Vyas, J. Cavenagh, T. Stankovic, P. Moss, and C. Craddock. 2010. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116: 1908-1918.
31. Chinnasamy, N., J. A. Wargo, Z. Yu, M. Rao, T. L. Frankel, J. P. Riley, J. J. Hong, M. R. Parkhurst, S. A. Feldman, D. S. Schrump, et al. 2011. A TCR targeting the HLA-A0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 186: 685-696.
32. Rao, M., N. Chinnasamy, J. A. Hong, Y. Zhang, M. Zhang, S. Xi, F. Liu, V. E. Marquez, R. A. Morgan, and D. S. Schrump. 2011. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res. 71: 4192-4204.
33. Wargo, J. A., P. F. Robbins, Y. Li, Y. Zhao, M. El-Gamil, D. Caragacianu, Z. Zheng, J. A. Hong, S. Downey, D. S. Schrump, et al. 2009. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 58: 383-394.
34. Weiser, T. S., Z. S. Guo, G. A. Ohnmacht, M. L. Parkhurst, P. Tong-On, F. M. Marincola, M. R. Fischette, X. Yu, G. A. Chen, J. A. Hong, et al. 2001. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 24: 151-161.
35. Cruz, C. R., U. Gerdemann, A. M. Leen, J. A. Shafer, S. Ku, B. Tzou, T. M. Horton, A. Sheehan, A. Copeland, A. Younes, et al. 2011. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. [Published erratum appears in 2012 Clin. Cancer Res. 18: 913.] Clin. Cancer Res. 17: 7058-7066.
36. Schrump, D. S. 2012. Targeting epigenetic mediators of gene expression in thoracic malignancies. Biochim. Biophys. Acta 1819: 836-845.
37. Zhuang, R., Y. Zhu, L. Fang, X. S. Liu, Y. Tian, L. H. Chen, W. M. Ouyang, X. G. Xu, J. L. Jian, A. O. Güre, et al. 2006. Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. Cancer Immun. 6: 7.
38. Schmid, D. A., M. B. Irving, V. Posevitz, M. Hebeisen, A. Posevitz-Fejfar, J. C. Sarria, R. Gomez-Eerland, M. Thome, T. N. Schumacher, P. Romero, et al. 2010. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184: 4936-4946.
39. Thomas, S., S. A. Xue, C. R. Bangham, B. K. Jakobsen, E. C. Morris, and H. J. Stauss. 2011. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood 118: 319-329.
40. Govers, C., Z. Sebestyén, M. Coccoris, R. A. Willemsen, and R. Debets. 2010. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol. Med. 16: 77-87.
41. Sommermeyer, D., J. Neudorfer, M. Weinhold, M. Leisegang, B. Engels, E. Noessner, M. H. Heemskerk, J. Charo, D. J. Schendel, T. Blankenstein, et al. 2006. Designer T cells by T cell receptor replacement. Eur. J. Immunol. 36: 3052-3059.
42. Govers, C., Z. Sebestyén, J. Roszik, M. van Brakel, C. Berrevoets, Á. Szöor, K. Panoutsopoulou, M. Broertjes, T. Van, G. Vereb, et al. 2014. TCRs genetically linked to CD28 and CD3ϵ do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity. J. Immunol. 193: 5315-5326.
43. Irving, M., V. Zoete, M. Hebeisen, D. Schmid, P. Baumgartner, P. Guillaume, P. Romero, D. Speiser, I. Luescher, N. Rufer, and O. Michielin. 2012. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J. Biol. Chem. 287: 23068-23078.
44. Hebeisen, M., L. Baitsch, D. Presotto, P. Baumgaertner, P. Romero, O. Michielin, D. E. Speiser, and N. Rufer. 2013. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J. Clin. Invest. 123: 1044-1056.
45. Hong, J. A., Y. Kang, Z. Abdullaev, P. T. Flanagan, S. D. Pack, M. R. Fischette, M. T. Adnani, D. I. Loukinov, S. Vatolin, J. I. Risinger, et al. 2005. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 65: 7763-7774.
46. Covre, A., S. Coral, A. M. Di Giacomo, P. Taverna, M. Azab, and M. Maio. 2015. Epigenetics meets immune checkpoints. Semin. Oncol. 42: 506-513.
47. Weintraub, K. 2016. Take two: combining immunotherapy with epigenetic drugs to tackle cancer. Nat. Med. 22: 8-10.
48. Chiappinelli, K. B., P. L. Strissel, A. Desrichard, H. Li, C. Henke, B. Akman, A. Hein, N. S. Rote, L. M. Cope, A. Snyder, et al. 2015. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. [Published erratum appears in 2016 Cell 164: 1073.] Cell 162: 974-986.
49. Peng, D., I. Kryczek, N. Nagarsheth, L. Zhao, S. Wei, W. Wang, Y. Sun, E. Zhao, L. Vatan, W. Szeliga, et al. 2015. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527: 249-253.
50. Braiteh, F., A. O. Soriano, G. Garcia-Manero, D. Hong, M. M. Johnson, Lde. P. Silva, H. Yang, S. Alexander, J. Wolff, and R. Kurzrock. 2008. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. Cancer Res. 14: 6296-6301.
51. Kuendgen, A., G. Bug, O. G. Ottmann, D. Haase, J. Schanz, B. Hildebrandt, K. Nachtkamp, J. Neukirchen, A. Dienst, R. Haas, et al. 2011. Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clin. Epigenetics 2: 389-399.
52. Voso, M. T., V. Santini, C. Finelli, P. Musto, E. Pogliani, E. Angelucci, G. Fioritoni, G. Alimena, L. Maurillo, A. Cortelezzi, et al. 2009. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin. Cancer Res. 15: 5002-5007.
53. Raffoux, E., A. Cras, C. Recher, P. Y. Boëlle, A. de Labarthe, P. Turlure, J. P. Marolleau, O. Reman, C. Gardin, M. Victor, et al. 2010. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 1: 34-42.
54. Soriano, A. O., H. Yang, S. Faderl, Z. Estrov, F. Giles, F. Ravandi, J. Cortes, W. G.Wierda, S. Ouzounian, A. Quezada, et al. 2007. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110: 2302-2308.
55. Klenova, E. M., H. C. Morse, III, R. Ohlsson, and V. V. Lobanenkov. 2002. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin. Cancer Biol. 12: 399-414.
56. Loukinov, D. I., E. Pugacheva, S. Vatolin, S. D. Pack, H. Moon, I. Chernukhin, P. Mannan, E. Larsson, C. Kanduri, A. A. Vostrov, et al. 2002. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc. Natl. Acad. Sci. USA 99: 6806-6811.
57. Eng, K. H., and T. Tsuji. 2014. Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers. PLoS One 9: e111586.
58. Parker, K. C., M. A. Bednarek, L. K. Hull, U. Utz, B. Cunningham, H. J. Zweerink, W. E. Biddison, and J. E. Coligan. 1992. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J. Immunol. 149: 3580-3587.
59. Hunt, D. F., R. A. Henderson, J. Shabanowitz, K. Sakaguchi, H. Michel, N. Sevilir, A. L. Cox, E. Appella, and V. H. Engelhard. 1992. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255: 1261-1263.
60. Engels, B., V. H. Engelhard, J. Sidney, A. Sette, D. C. Binder, R. B. Liu, D. M. Kranz, S. C. Meredith, D. A. Rowley, and H. Schreiber. 2013. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23: 516-526.
61. Wang, Y., K. J. Han, X. W. Pang, H. A. Vaughan, W. Qu, X. Y. Dong, J. R. Peng, H. T. Zhao, J. A. Rui, X. S. Leng, et al. 2002. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J. Immunol. 169: 1102-1109.